Top

Published in:

01-06-2009 | Short Report

Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs

Authors: L.-C. Steve Wang, Lai-Ming Ching, James W. Paxton, Philip Kestell, Rachel Sutherland, Li Zhuang, Bruce C. Baguley

Published in: Investigational New Drugs | Issue 3/2009

Summary

Aim: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) (ASA404), a low molecular weight antivascular drug currently in clinical trial, acts both directly on the tumour vascular endothelium and indirectly through the induction of inflammatory cytokines and other vasoactive molecules from macrophages and other host cells. We wished to determine whether co-administration of non-steroidal anti-inflammatory drugs (NSAIDs) could modulate the antivascular effects of DMXAA in mice. Methods: The effects of diclofenac, salicylate, ibuprofen, celecoxib and rofecoxib on the antitumour response to DMXAA were compared using growth delay assays of Colon 38 adenocarcinomas in C57Bl mice. Concentrations of DMXAA in mice were measured by high performance liquid chromatography. Results: Administration of DMXAA alone (25 mg/kg i.p.) or of NSAIDs alone induced small tumour growth delays from 2 to 7 days. Co-administration of each of the NSAIDs augmented DMXAA effects with tumour growth delays from 4.5 to >20 days. The possibility of a pharmacokinetic interaction was investigated using diclofenac and it was found that diclofenac did not affect DMXAA pharmacokinetics. Conclusions: NSAIDs increase the antitumour activity of DMXAA in a murine tumour model. The effects are consistent with hypothesis that NSAIDs antagonises some of the protective effects of prostaglandins released in response to vascular injury. Co-administration of NSAIDs with DMXAA might be considered as a possible strategy for use in combination cancer therapy.

Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423–435 doi:10.1038/nrc1628 CrossRefPubMed

Philpott M, Baguley BC, Ching LM (1995) Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36:143–148 doi:10.1007/BF00689199 CrossRefPubMed

Baguley BC (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol 4:141–148 doi:10.1016/S1470–2045(03)01018–0 CrossRefPubMed

Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86:1937–1942 doi:10.1038/sj.bjc.6600368 CrossRefPubMed

Ching LM, Zwain S, Baguley BC (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90:906–910 doi:10.1038/sj.bjc.6601606 CrossRefPubMed

Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC (2005) Mechanisms of tumor vascular shut-down induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA); increased tumor vascular permeability. Int J Cancer 116:322–326 doi:10.1002/ijc.21005 CrossRefPubMed

McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M et al (2006) 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12:1776–1784 doi:10.1158/1078–0432.CCR-05–1939 CrossRefPubMed

McKeage MJ (2008) The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs 17:23–29 doi:10.1517/13543784.17.1.23 CrossRefPubMed

Sanborn R, Blanke CD (2005) Cyclooxygenase-2 inhibition in colorectal cancer: Boom or bust? Semin Oncol 32:69–75 doi:10.1053/j.seminoncol.2004.09.035 CrossRefPubMed

10.

Pereg D, Lishner M (2005) Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 258:115–123 doi:10.1111/j.1365–2796.2005.01519.x CrossRefPubMed

11.

Yang H, Majno P, Morel P, Toso C, Triponez F, Oberholzer J et al (2002) Prostaglandin E(1) protects human liver sinusoidal endothelial cell from apoptosis induced by hypoxia reoxygenation. Microvasc Res 64:94–103 doi:10.1006/mvre.2002.2404 CrossRefPubMed

12.

Ching LM, Joseph WR, Baguley BC (1992) Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid. Biochem Pharmacol 44:192–195 doi:10.1016/0006–2952(92)90058-Q CrossRefPubMed

13.

Kestell P, Zhao L, Baguley BC, Palmer BD, Muller G, Paxton JW et al (2000) Modulation of the pharmacokinetics of the antitumour agent 5,6- dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer Chemother Pharmacol 46:135–141 doi:10.1007/s002800000131 CrossRefPubMed

14.

Zhou S, Paxton JW, Kestell P, Tingle MD, Ching LM (2001) In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. Cancer Chemother Pharmacol 47:319–326 doi:10.1007/s002800000249 CrossRefPubMed

15.

Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 72:339–343PubMed

16.

Zhao L, Kestell P, Philpott M, Ching LM, Zhuang L, Baguley BC (2001) Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 47:491–497 doi:10.1007/s002800000267 CrossRefPubMed

17.

Baguley BC, Wilson WR (2002) Potential of DMXAA combination therapy for solid tumors. Expert Rev Anticancer Ther 2:593–603 doi:10.1586/14737140.2.5.593 CrossRefPubMed

18.

Bellnier DA, Gollnick SO, Camacho SH, Greco WR, Cheney RT (2003) Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Cancer Res 63:7584–7590PubMed

19.

Fingar VH (1996) Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14:323–328PubMed

20.

Ferrario A, Fisher AM, Rucker N, Gomer CJ (2005) Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 20:9473–9478 doi:10.1158/0008–5472.CAN-05–1659 CrossRef

21.

Naisbitt DJ, Sanderson LS, Meng X, Stachulski AV, Clarke SE, Park BK (2007) Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicol Lett 168:45–50 doi:10.1016/j.toxlet.2006.10.014 CrossRefPubMed

22.

Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K et al (2008) Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83:1136–1144 doi:10.1189/jlb.0907611 CrossRefPubMed

23.

Thomsen LL, Ching LM, Zhuang L, Gavin JB, Baguley BC (1991) Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51:77–81PubMed

Title: Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs
Authors: L.-C. Steve Wang
Lai-Ming Ching
James W. Paxton
Philip Kestell
Rachel Sutherland
Li Zhuang
Bruce C. Baguley
Publication date: 01-06-2009
Publisher: Springer US
Published in: Investigational New Drugs / Issue 3/2009
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-008-9167-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2009

Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

Nimbolide a limonoid from Azadirachta indica inhibits proliferation and induces apoptosis of human choriocarcinoma (BeWo) cells

Antioxidant and anticancer efficacy of hesperidin in benzo(a)pyrene induced lung carcinogenesis in mice

N-benzoxazol-2-yl-N′-1-(isoquinolin-3-yl-ethylidene)-hydrazine, a novel compound with antitumor activity, induces radicals and dissipation of mitochondrial membrane potential

A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer